Is Myomo, Inc. overvalued or undervalued?

As of 6 November 2017, Myomo, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued. Key ratios indicate significant financial distress, with a price-to-book value of 4.94, an EV to EBITDA of -18.39, and a return on equity (ROE) of -26.80%.
In comparison to its peers, Myomo's valuation metrics are concerning; for instance, Sally Beauty Holdings, Inc. has a P/E ratio of 4.6171 and an EV to EBITDA of 4.2486, highlighting a stark contrast in financial health. Additionally, Herbalife Ltd. also carries a risky valuation with an EV to EBITDA of 4.9908. The company's recent stock performance has been poor, with a year-to-date return of -64.75% compared to a modest 2.44% return from the S&P 500, further reinforcing the notion that Myomo is overvalued in its current state.